| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1896 | 2021 |
| Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study RJ Wilkinson, M Llewelyn, Z Toossi, P Patel, G Pasvol, A Lalvani, ... The Lancet 355 (9204), 618-621, 2000 | 1108 | 2000 |
| Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial OA Cornely, DW Crook, R Esposito, A Poirier, MS Somero, K Weiss, ... The Lancet infectious diseases 12 (4), 281-289, 2012 | 924 | 2012 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 727 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 547 | 2022 |
| Superantigens: microbial agents that corrupt immunity M Llewelyn, J Cohen The Lancet infectious diseases 2 (3), 156-162, 2002 | 462 | 2002 |
| Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1β on tuberculosis RJ Wilkinson, P Patel, M Llewelyn, CS Hirsch, G Pasvol, G Snounou, ... Journal of Experimental Medicine 189 (12), 1863-1874, 1999 | 442 | 1999 |
| Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing NC Gordon, JR Price, K Cole, R Everitt, M Morgan, J Finney, AM Kearns, ... Journal of clinical microbiology 52 (4), 1182-1191, 2014 | 395 | 2014 |
| The antibiotic course has had its day MJ Llewelyn, JM Fitzpatrick, E Darwin, C Gorton, J Paul, TEA Peto, ... Bmj 358, 2017 | 358 | 2017 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ... The Lancet 397 (10274), 605-612, 2021 | 350 | 2021 |
| Clinical management of Staphylococcus aureus bacteraemia GE Thwaites, JD Edgeworth, E Gkrania-Klotsas, A Kirby, R Tilley, ... The Lancet infectious diseases 11 (3), 208-222, 2011 | 339 | 2011 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 336 | 2021 |
| Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies AJ Kaasch, G Barlow, JD Edgeworth, VG Fowler Jr, M Hellmich, ... Journal of Infection 68 (3), 242-251, 2014 | 324 | 2014 |
| Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials DW Crook, AS Walker, Y Kean, K Weiss, OA Cornely, MA Miller, ... Clinical Infectious Diseases 55 (suppl_2), S93-S103, 2012 | 321 | 2012 |
| Identifying lineage effects when controlling for population structure improves power in bacterial association studies SG Earle, CH Wu, J Charlesworth, N Stoesser, NC Gordon, TM Walker, ... Nature microbiology 1 (5), 1-8, 2016 | 301 | 2016 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 297 | 2022 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 220 | 2021 |
| Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial GE Thwaites, M Scarborough, A Szubert, E Nsutebu, R Tilley, J Greig, ... The Lancet 391 (10121), 668-678, 2018 | 204 | 2018 |
| Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome … JR Price, K Cole, A Bexley, V Kostiou, DW Eyre, T Golubchik, DJ Wilson, ... The Lancet Infectious Diseases 17 (2), 207-214, 2017 | 202 | 2017 |
| Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a … APS Munro, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, ... The Lancet Infectious Diseases 22 (8), 1131-1141, 2022 | 184 | 2022 |